FY2027-H1First statedAnnual report
「Tillotts Pharma AG, the Company’s Swiss subsidiary, entered into an equity transfer agreement with Aenova Holding GmbH on 23 October 2026 (Swiss time) to acquire all equity interests in Haupt Pharma Wülfling GmbH.
By acquiring all equity interests in Haupt Pharma Wülfling GmbH and bringing manufacturing at the site in-house, Tillotts Pharma AG will significantly expand its pharmaceutical manufacturing base and be able to control manufacturing capacity, production planning and quality control more directly and flexibly. This will further strengthen the long-term stable supply structure for its products.
Business combination date: January 2027 or later (planned)
Voting rights to be acquired: 100%」
Tillotts Pharma AG announced a plan to acquire all equity interests in Haupt Pharma Wülfling GmbH, which has handled most Asacol manufacturing, and bring manufacturing in-house. The business combination is planned for January 2027 or later, and the acquisition price and other details have not been determined.